Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1 Antibody, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-up Efficacy and Safety Data

Main Article Content

Taofeek Owonikoko
Kyriakos Papadopoulos
Melissa Johnson
et al.



Abstract not available.


Disclosures: Study sponsored by Regeneron Pharmaceuticals.

Most read articles by the same author(s)

1 2 > >>